Schedule Kratom? Promoted By Former US FDA Commissioner, Opposed By Former Top HHS Official
Executive Summary
Former commissioner Scott Gottlieb and former HHS health chief Brett Giroir make clear they haven’t changed their minds in Twitter posts following FDA kratom seizure announcement.
You may also be interested in...
Arizona Supplement Firm’s Problems Start With COVID-19 Claims, Reach SARMS, ED Drug
CDER notes in update to COVID-19 enforcement and other actions that Umbrella Labs made unlawful claims to prevent and treat the virus. Announcement didn’t note those claims weren’t first among violations identified in a warning letter to the firm.
US HHS Pulled Recommendation To Make Kratom A Controlled Substance, But Kept Mum On Change
HHS released to industry proponents Reps. Mark Pocan and Morgan Griffith the letter it submitted in 2018 notifying DEA that it was rescinding recommendation it made in 2017 to list kratom active ingredients mitragynine and 7-hydroxymitragynine under Schedule I of the CSA.
DEA Takes Comments On Kratom, But Keeps Eye On Scheduling
DEA will accept comments through Dec. 1 on its proposal to move the active materials in kratom into Schedule I under CSA to avoid an imminent hazard to public safety.